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EDITORIAL

The Third Epoch: ‘‘Kidney Plus’’
Transplantation

T

he first epoch of kidney transplantation
began over a century ago when successful,
experimental kidney transplantations were performed on animals at the Vienna Medical School
(1902). However, the initial success was subsequently beset by noteworthy failures in kidney
transplantation including rabbit-to-human
attempts (France, 1909), human-to-human
allograft implantation without immunosuppression (1950), and partially successful
human-to-human transplantations under the
aegis of glucocorticoid steroid congeners
(1950s) after the recognition of the etiopathogenic importance of the immune system to rejection. This first epoch of kidney transplantation
ended on December 23, 1954. On that day, the
team of Dr John Murray successfully transplanted the kidney of an identical twin to his
brother.
Buoyed by Murray’s ‘‘perfect match’’ surgery, the science of organ transplantation
entered its second epochal stage. Continual
improvements in tissue typing, organ preservation and procurement, and then, immunosuppression followed rapidly during the
1960s and complemented advances in surgical
technique. Kidney transplantation exponentially became an increasingly prevalent phenomenon, and superior outcomes to those
receiving chronic renal replacement therapy
were apparent to those so involved and
patients! In parallel with these burgeoning
activities, the administrative components of
transplantation evolved and our present-day
regulatory organizations evolved from these
critical efforts. In fact, the United Network

for Organ Sharing celebrated its 25th anniversary in March 2009.
Noteworthy is that the agencies and societies
dedicated to kidney transplantation have established clearcut outcome metrics for recipients
and the not-to-be forgotten donors. The bar
was set ‘‘high,’’ and the high standards imposed
are, in part, responsible for why the kidney has
been transplanted successfully far in excess of
any other organ, with the following laudable
outcome data: (1) 1-year patient survival after
deceased-donor transplantation is 94.1% (unadjusted), (2) 1-year patient survival after livingdonor transplantation is 98%, (3) allograft
survival after deceased-donor transplantation
is 89.7% (unadjusted), and (4) allograft survival
after living-donor transplantation is 95.1%. All
of this is underscored by the compelling fact
that kidney transplantation is no longer novel;
it is ‘‘mainstream’’ as espoused on the United
Network for Organ Sharing web site. Granted,
nearly 100,000 persons have undergone successful kidney transplantation, and the annual
number of transplants exceeds 18,000. Unfortunately, despite these positive data, currently,
nearly 78,000 individuals await renal allografts.
With this as pretext, the third epoch of kidney transplantation is characterized by dualorgan transplantion involving the kidney as
one half of the combination, namely, ‘‘kidney
plus (another organ)’’ transplantation.
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Presently, it is not uncommon for patients to
undergo evaluations for dual-organ transplantation: simultaneous pancreas-kidney,
orthotopic liver-kidney, and heart-kidney
transplantations. However, these combined
procedures remain fraught with hazard, even
when practiced at ‘‘centers of excellence.’’ Previously, the excessive mortality associated
with type 1 diabetes precluded many of the afflicted from kidney transplantation. However,
improvements in the care of such individuals
have substantially prolonged patients’ lives
and their probabilities of developing nephropathy and end-stage kidney failure. Thus, simultaneous pancreas-kidney transplantation
is a function of medical progress and relevant
to patients who could not achieve adequate
glycemic and/or blood pressure control in
the period preceding the onset of diabetic kidney disease. Comparable advances in the
treatment of end-stage liver disease have
taken place. Despite the increasing prevalence
of progressive liver disorders, primarily those
attributable to the hepatitis C virus, alcoholic
liver disease, and now nonalcoholic steatohepatitis, many patients have the opportunity
for longer-term survival via orthotopic liver
transplantation. With desperate illness comes
desperate measures, and many acute or
chronic ‘‘liver’’ patients with high model for
end-stage liver disease scores develop acute
kidney injury within the rubric of type 1 or
type 2 hepatorenal syndrome. Hepatorenal
syndrome occurs in 10% of hospitalized
patients with cirrhosis and ascites and has
a frequency of 8% to 20% per year in decompensated cirrhosis.
In addition, it is not atypical for patients
who have already undergone solitary-organ,
nonkidney transplantation to ‘‘abruptly’’
appear with kidney disease—the consequence
of prolonged and perhaps unduly excessive
exposure to nephrotoxic agents, principally,
calcineurin inhibitors that have been shown
to promote tubulointerstitial fibrosis through
a panoply of mechanisms, including those
that involve the renal microvasculature and
transforming growth factor-beta. Protocol biopsies have confirmed the onset of histologic
damage within a relatively brief interval (less
than 2 years), despite ‘‘low therapeutic’’ drug
levels of calcineurin inhibitors in solitary renal

allograft recipients. By contrast, recipients of
hepatic and cardiac organs have often been
treated to comparatively much higher calcineurin inhibitor levels, and it is unsurprising
that CKD is present and essentially ‘‘expected’’ in long-term survivors. Furthermore,
at the time when CKD is discovered, the
cardiac transplant recipient will often manifest variable degrees of decompensation,
thereby compounding the preexistent clinical
burden with the cardiorenal syndrome.
Like the two epochs preceding it, the third epoch is characterized by a period of exploration,
advancements in technology, and informed
specification of those medical and surgical
methods and techniques that will hopefully
optimize patient results. Such recommendations characteristically stem from consensus
opinions rendered by multilateral congresses
comprised of the relevant, pursuant parties.
Thus, there are ‘‘gray zones’’ for ‘‘kidney
plus’’ transplantation, wherein ‘‘best practice’’
guidance from clinical trials is lacking for these
patients. In this issue of Advances in Chronic
Kidney Disease, the Guest Editor, Connie L. Davis, MD, has coordinated a series of articles
dedicated toward improving our understanding of the issues that confront kidney transplantation physicians who are involved with
post-heart, -liver, and -lung patients as well
as dual-organ transplantation evaluations.
The unique problems that differentiate these
individuals from conventional kidney-only
transplant recipients are enumerated. Moreover, valuable logical and practical advice
regarding the approach to caring for these patients is rendered by the authors.
In particular, the optimal management of
kidney failure of cardiac, liver, and lung failure in the pretransplant interval is reviewed.
Here, optimizing renal replacement therapy
when applicable is critical, and the timing of
therapy is equally important as the technique.
In addition, published recommendations relevant to patient selection for dual-organ transplantations are presented. In parallel, the
issue of establishing a renal diagnosis by biopsy in azotemic patients presenting with heart
or liver failure also resurfaces. Lastly, expert
commentaries on individualized immunosuppressive therapy and the requirement for vigilance regarding transmissions of infectious
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disorders from donors to recipients are provided.
Taken together, I echo the sentiments of
Dr Murray, who stated that his lofty accomplishment belonged not to him alone but to
the team that he guided. Yes, it will truly require a coordinated, focused, and dedicated
effort among the multiple disciplines that
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interact on behalf of ‘‘kidney plus’’ transplant
recipients, in order to not only aspire to but
also to achieve the outcomes that these patients seek and deserve.
Jerry Yee, MD
Editor

